Rash, hepatotoxicity and hyperbilirubinemia among kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission

Pediatric Infectious Disease Journal

Volumn 31, Issue 11, 2012, Pages 1155-1157

  Minniear, Timothy D ^a,b   Zeh, Clement ^b,c   Polle, Nicholas ^d   Masaba, Rose ^c   Peters, Philip J ^b   Oyaro, Boaz ^c   Akoth, Benta ^c   Ndivo, Richard ^b   Angira, Frank ^b   Mills, Lisa A ^b,c   Thomas, Timothy K ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d MINISTRY OF HEALTH   (Kenya)

Author keywords

antiretroviral agents; HIV; infant; newborn; toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; BREAST MILK; CLINICAL ARTICLE; DRUG ERUPTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFANT; INFANT DISEASE; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; MALE; MOTHER TO CHILD TRANSMISSION; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS TRANSMISSION;

ADULT; AGING, PREMATURE; ANTI-HIV AGENTS; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; HYPERBILIRUBINEMIA; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; NELFINAVIR; NEVIRAPINE; PREGNANCY;

EID: 84867889296     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318267ef6a     Document Type: Article

References (12)

1. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO Press; 2010.
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: WHO Press; 2009.
3. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009;53:1170-1176.
4. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011; pp 1-268. Available at: http://aidsinfo. nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed November 19, 2011.
5. Weidle PJ, Zeh C, Martin A, et al. Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir. Antimicrob Agents Chemother. 2011;55:5168-5171.
6. Thomas TK, Masaba R, Borkowf CB, et al. Highly active antiretroviral therapy to prevent mother-to-child HIV transmission through breastfeeding in Kenya: The Kisumu Breastfeeding Study. PLoS Med. 2011;8:1-12.
7. National Institutes of Health. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events [National Institute of Allergy and Infectious Diseases website]. December 2004. Available at: http://www. niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/ daidsaegradingtable.pdf. Accessed February 4, 2011.
8. American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114: 297-316.
9. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119-129. (Pubitemid 351962035)
10. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials. Lancet. 2008;372:300-313.
11. Porter ML, Dennis BL. Hyperbilirubinemia in the term newborn. Am Fam Physician. 2002;65:599-606.
12. De Maat MM, Mathôt RA, Veldkamp AI, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res. 2002;46:295-300. (Pubitemid 35300770)